Literature DB >> 16395834

Drotrecogin alfa (activated) in severe sepsis.

J K Baillie, G Murray.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16395834

Source DB:  PubMed          Journal:  N Engl J Med        ISSN： 0028-4793            Impact factor:   91.245


× No keyword cloud information.
  6 in total

1.  How many patients with severe sepsis are needed to confirm the efficacy of drotrecogin alfa activated? A Bayesian design.

Authors:  Andre C Kalil; Junfeng Sun
Journal:  Intensive Care Med       Date:  2008-05-27       Impact factor: 17.440

Review 2.  Activated protein C in sepsis: the promise of nonanticoagulant activated protein C.

Authors:  Hartmut Weiler; Wolfram Ruf
Journal:  Curr Opin Hematol       Date:  2008-09       Impact factor: 3.284

3.  Medical guidelines and performance measures: the need to keep them free of industry influence.

Authors:  Peter Q Eichacker; Charles Natanson
Journal:  Mens Sana Monogr       Date:  2008-01

4.  Drotrecogin alfa (activated) should not be used in patients with severe sepsis and low risk for death.

Authors:  Sanjay Gupta; Eric B Milbrandt; Lakshmipathi Chelluri
Journal:  Crit Care       Date:  2006       Impact factor: 9.097

Review 5.  Treatable traits and therapeutic targets: Goals for systems biology in infectious disease.

Authors:  Clark D Russell; J Kenneth Baillie
Journal:  Curr Opin Syst Biol       Date:  2017-04-27

6.  Growing insights into the potential benefits and risks of activated protein C administration in sepsis: a review of preclinical and clinical studies.

Authors:  Laith Altaweel; Daniel Sweeney; Xizhong Cui; Amisha Barochia; Charles Natanson; Peter Q Eichacker
Journal:  Biologics       Date:  2009-09-15
  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.